As all anti-hTNFR2 antagonists have been designed to eliminate TNFR2-expressing cells (tumor cells or Tregs) by antibody-dependent cellular cytotoxicity (ADCC), they will not help to decipher the impact of TNFR2 inhibition in human Tregs. Here, TNFRSF1B is linked to neoplasm.